Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
by Zacks Equity Research
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
by Zacks Equity Research
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
by Zacks Equity Research
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
by Zacks Equity Research
Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA
by Zacks Equity Research
Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA. Shares down.
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeglea (AGLE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?
by Zacks Equity Research
Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.
Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
by Zacks Equity Research
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AGLE) Outperforming Other Medical Stocks This Year?
Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
by Zacks Equity Research
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio